Cl-Amidine trifluoroacetate salt: High-Potency PAD4 Inhibitor for Epigenetic & Disease Research

Executive Summary: Cl-Amidine (trifluoroacetate salt) is a crystalline compound that potently inhibits protein arginine deiminase 4 (PAD4) through selective, active-site antagonism, enabling precise modulation of histone citrullination and downstream epigenetic states (product page). Dose-dependent PAD4 inhibition by Cl-Amidine is validated both biochemically and in murine models of septic shock, where it restores innate immunity and reduces pro-inflammatory cytokines (Nelson et al. 2022). The compound demonstrates superior solubility in DMSO and water, facilitating diverse workflow integration. Compared to related inhibitors, Cl-Amidine shows higher potency and selectivity, minimizing off-target effects. The compound is strictly intended for research use and should be stored at -20°C for optimal stability.

Biological Rationale

PAD4 is an enzyme catalyzing the deimination of arginine residues to citrulline on histones, a critical post-translational modification regulating chromatin structure and gene expression. Dysregulated PAD4 activity is implicated in pathologies such as cancer, rheumatoid arthritis, and sepsis via aberrant epigenetic programming and immune cell dysfunction (see BCA-Protein article). Cl-Amidine (trifluoroacetate salt) enables targeted investigation of PAD4’s roles by providing high selectivity and potency in cellular and animal models. This article extends previous reviews by providing structured, machine-readable evidence and explicit workflow integration contrasts.

Mechanism of Action of Cl-Amidine (trifluoroacetate salt)

Cl-Amidine is a covalent, irreversible inhibitor that selectively binds the active site of PAD4. This antagonism prevents conversion of histone arginine to citrulline, blocking downstream chromatin remodeling and gene expression changes. Cl-Amidine’s molecular structure features an amidine group and a trifluoroacetate counterion, enhancing both potency and aqueous solubility (soluble at ≥20.55 mg/mL in DMSO, ≥9.53 mg/mL in water with ultrasonic assistance) (ApexBio). The compound is insoluble in ethanol. By blocking PAD4 activity, Cl-Amidine modulates immune response, cell differentiation, and apoptosis, with significant effects in models of inflammation and malignancy (HDAC1.com; this article provides updated evidence tables and limitations not found in prior summaries).

Evidence & Benchmarks

• Cl-Amidine exhibits dose-dependent inhibition of PAD4 activity in vitro, with an IC₅₀ value in the low micromolar range, outperforming F-amidine in comparable assays (Nelson et al. 2022).
• In CLP-induced septic shock murine models, Cl-Amidine administration improved 7-day survival rates and preserved bone marrow and thymic cellularity (Nelson et al. 2022).
• Cl-Amidine treatment enhances bacterial clearance and reduces pro-inflammatory cytokines (e.g., IL-6, TNF-α) in vivo, indicating restoration of innate immunity (Nelson et al. 2022).
• The crystalline solid form (molecular weight 424.8) ensures consistent dosing and reagent quality in biochemical and cellular assays (ApexBio).
• Cl-Amidine is not suitable for diagnostic or therapeutic use in humans; efficacy and safety are established only in research models (ApexBio).

Applications, Limits & Misconceptions

Cl-Amidine (trifluoroacetate salt) is widely used in:

• Epigenetic research: Dissecting the role of histone citrullination in gene regulation.
• Cancer models: Investigating PAD4-mediated pathways in tumorigenesis and synthetic lethality approaches (A-MSH.com; this article updates mechanistic links to synthetic lethality, expanding on prior discussions).
• Autoimmune and inflammatory disease studies: Modeling rheumatoid arthritis and sepsis.
• PAD4 enzyme activity assays: Benchmarking inhibitor potency and specificity.

Common Pitfalls or Misconceptions

• Cl-Amidine is not a general PAD inhibitor; potency and selectivity are highest for PAD4.
• The compound is not suitable for clinical or diagnostic applications; for research use only.
• Long-term storage of prepared solutions (>1 week) at room temperature leads to potency loss.
• Solubility is poor in ethanol; use DMSO or water (with sonication) for preparation.
• PAD4-independent gene regulation events are not affected by Cl-Amidine.

Workflow Integration & Parameters

For PAD4 enzyme activity assays, dissolve Cl-Amidine (trifluoroacetate salt) at ≥20.55 mg/mL in DMSO. For in vivo studies, water-based solutions (≥9.53 mg/mL with ultrasonic assistance) are recommended. Store the solid at -20°C, and prepare fresh working solutions before use. The compound is compatible with cell culture, immunoblot, and animal protocols. Avoid prolonged pre-incubation or freeze-thaw cycles. When benchmarking new workflows, Cl-Amidine can be contrasted with F-amidine to confirm selectivity and potency (JNJ-38877605.com; this article provides recent troubleshooting tips and application-specific advice).

Conclusion & Outlook

Cl-Amidine (trifluoroacetate salt, C3829) provides a robust, validated platform for targeted PAD4 inhibition in epigenetic, cancer, and immunology research. Its superior solubility, selectivity, and in vivo efficacy underpin its value as a benchmarking standard. Future studies may expand its use in novel synthetic lethality screens and translational disease models, but clinical use remains out of scope. For ordering and detailed specifications, consult the product page.